Should I buy or sell Lifecore Biomedical stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lifecore Biomedical in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LFCR shares. View LFCR analyst ratings or view top-rated stocks .

What is Lifecore Biomedical's stock price target for 2024?

2 brokers have issued 12-month price objectives for Lifecore Biomedical's stock. Their LFCR share price targets range from $9.00 to $10.00. On average, they anticipate the company's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 50.4% from the stock's current price. View analysts price targets for LFCR or view top-rated stocks among Wall Street analysts .

How have LFCR shares performed in 2024?

Lifecore Biomedical's stock was trading at $6.19 on January 1st, 2024. Since then, LFCR stock has increased by 2.0% and is now trading at $6.3150. View the best growth stocks for 2024 here .

When is Lifecore Biomedical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 6th 2024. View our LFCR earnings forecast .

What guidance has Lifecore Biomedical issued on next quarter's earnings?

Lifecore Biomedical issued an update on its FY 2024 earnings guidance on Monday, April, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $125.0 million-$130.0 million, compared to the consensus revenue estimate of $123.6 million.

How do I buy shares of Lifecore Biomedical?

Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LFCR

Lifecore Biomedical (LFCR) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free LFCR Stock Alerts

$6.32

-0.21 (-3.22%)

(As of 04/18/2024 ET)

Compare

Today's Range: $6.04
▼
$6.53
50-Day Range: $5.01
▼
$8.55
52-Week Range: $3.78
▼
$11.45

Volume: 149,567 shs
Average Volume: 195,556 shs
Market Capitalization: $191.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.50

Get Lifecore Biomedical alerts:

Lifecore Biomedical MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 50.4% Upside
$9.50 Price Target
Short Interest: Bearish
6.04% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.33
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.42) to ($0.14) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.37 out of 5 stars

Medical Sector

719th out of 919 stocks

Pharmaceutical Preparations Industry

315th out of 405 stocks

3.3

Analyst's Opinion

Consensus Rating
Lifecore Biomedical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Lifecore Biomedical has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.04% of the float of Lifecore Biomedical has been sold short.
Short Interest Ratio / Days to Cover
Lifecore Biomedical has a short interest ratio ("days to cover") of 8.7.
Change versus previous month
Short interest in Lifecore Biomedical has recently increased by 1.70%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Lifecore Biomedical does not currently pay a dividend.
Dividend Growth
Lifecore Biomedical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LFCR.

1.9

News and Social Media Coverage

News Sentiment
Lifecore Biomedical has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Lifecore Biomedical this week, compared to 2 articles on an average week.
MarketBeat Follows
Only 2 people have added Lifecore Biomedical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lifecore Biomedical insiders have not sold or bought any company stock.
Percentage Held by Insiders
14.61% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
83.36% of the stock of Lifecore Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Lifecore Biomedical are expected to grow in the coming year, from ($0.42) to ($0.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lifecore Biomedical is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lifecore Biomedical is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Lifecore Biomedical Stock (NASDAQ:LFCR)

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

LFCR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LFCR Stock News Headlines

April 17, 2024 | msn.com

Lifecore Biomedical (LFCR) Price Target Decreased by 11.11% to 8.16

April 12, 2024 | prnewswire.com

LFCR INVESTOR NEWS: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 12, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Lifecore Biomedical, Inc. - LFCR

April 11, 2024 | businesswire.com

ROSEN, A TOP RANKED LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation – LFCR, LNDC

April 11, 2024 | finance.yahoo.com

Do You Believe in the Upside Trajectory of Lifecore Biomedical (LFCR)?

April 4, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Lifecore Biomedical, Inc. - LFCR

April 1, 2024 | finance.yahoo.com

Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 28, 2024 | businesswire.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors

March 28, 2024 | businesswire.com

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors

March 28, 2024 | businesswire.com

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

March 28, 2024 | finanznachrichten.de

Lifecore Biomedical, Inc.: Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update

March 26, 2024 | businesswire.com

The Law Offices of Frank R. Cruz Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors

March 26, 2024 | globenewswire.com

Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update

March 24, 2024 | stockhouse.com

Lifecore Class Action Lawsuit Investigation News - Potential to Make Claim, Recover Losses, Contact Johnson Fistel, LLP

March 24, 2024 | businesswire.com

Lifecore Class Action Lawsuit Investigation News – Potential to Make Claim, Recover Losses, Contact Johnson Fistel, LLP

March 21, 2024 | businesswire.com

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

March 21, 2024 | businesswire.com

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Lifecore Biomedical, Inc. (LFCR)

March 21, 2024 | marketwatch.com

Lifecore Shares Slide After Strategic Review Ends With No Deal

March 20, 2024 | msn.com

Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

March 20, 2024 | finanznachrichten.de

Lifecore Biomedical, Inc.: Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023

March 20, 2024 | markets.businessinsider.com

Lifecore Biomedical: Board Concludes Review; To Execute Strategic Plan As Standalone Company

March 20, 2024 | msn.com

Lifecore Biomedical concludes strategic evaluation process, names new CEO

March 20, 2024 | globenewswire.com

Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes

March 20, 2024 | globenewswire.com

Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023

March 16, 2024 | finance.yahoo.com

LFCR Apr 2024 7.500 call

See More Headlines

Receive LFCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Fiscal Year End: 5/31/2024
Next Earnings (Estimated): 6/06/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LFCR
CUSIP: N/A
CIK: 1005286
Web: www.lifecore.com
Phone: (800) 454-1355
Fax: 650-368-9818
Employees: 459
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.50
High Stock Price Target: $10.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +50.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $103.27 million
Price / Sales: 1.85
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.14) per share
Price / Book: -45.11

Miscellaneous

Outstanding Shares: 30,320,000
Free Float: 25,892,000
Market Cap: $191.47 million
Optionable: Optionable
Beta: 1.03

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. James G. Hall (Age 61)
CEO, President & Director
Comp: $523.6k
Mr. John D. Morberg (Age 60)
Executive VP & CFO
Comp: $520.82k
Dr. Albert D. Bolles Ph.D. (Age 66)
President of Curation Foods, Inc.
Comp: $1.34M
Mr. Steve W. Laninga
Vice President of Operations
Dr. Kipling Thacker Ph.D. (Age 69)
VP & Chief Scientist
Mr. Aaron Perlitsh
Director of Internal Audit & Chief Compliance Officer
Mr. Darren M. Hieber
Senior Vice President of Corporate Development & Partnerships
Ms. Kara Morley
Senior Vice President of Human Resources
Ms. Jackie Q. Klecker
Executive VP & GM
Mr. Matt Augustson
Senior Vice President of Information Technology

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

LFCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Lifecore Biomedical stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lifecore Biomedical in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LFCR shares.
View LFCR analyst ratings or view top-rated stocks.
What is Lifecore Biomedical's stock price target for 2024?: 2 brokers have issued 12-month price objectives for Lifecore Biomedical's stock. Their LFCR share price targets range from $9.00 to $10.00. On average, they anticipate the company's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 50.4% from the stock's current price.
View analysts price targets for LFCR or view top-rated stocks among Wall Street analysts.
How have LFCR shares performed in 2024?: Lifecore Biomedical's stock was trading at $6.19 on January 1st, 2024. Since then, LFCR stock has increased by 2.0% and is now trading at $6.3150.
View the best growth stocks for 2024 here.
When is Lifecore Biomedical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, June 6th 2024.
View our LFCR earnings forecast.

What guidance has Lifecore Biomedical issued on next quarter's earnings?: Lifecore Biomedical issued an update on its FY 2024 earnings guidance on Monday, April, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $125.0 million-$130.0 million, compared to the consensus revenue estimate of $123.6 million.
How do I buy shares of Lifecore Biomedical?: Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LFCR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Lifecore Biomedical (LFCR) Stock Price, News & Analysis

Lifecore Biomedical MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Lifecore Biomedical Stock (NASDAQ:LFCR)

LFCR Stock Price History

LFCR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

LFCR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™